SIBN · SI-BONE, Inc. · Stock research

Current Thesis

SI-BONE is a sacroiliac-joint-fusion medtech at a profitability inflection, with a pelvic-trauma distribution leg through Smith+Nephew bolted onto the core franchise. The income statement is turning: Q1 2026 (reported 2026-05-11) posted $52.6M revenue (+11.2% YoY), ~79.8% gross margin, a narrowed $4.3M net loss and positive adjusted EBITDA, and management lifted FY2026 guidance to $230–233M (+14–16%) while pointing to a more pronounced second half. Since the last read the tape has gone nowhere fast — roughly $16.84 on 2026-07-02 to ~$16.62 by late July — still pinned under the $17.05 resistance shelf that overlaps the 200-day. Truist's 2026-07-16 target bump to $21 (from $18, Buy maintained) recovers ground the stock lost after a conservative-guidance-driven cut around the May print, yet the chart itself has neither reclaimed the 200-day nor stamped a decisive higher high. Growth is mid-teens, not the 30%+ that earns a momentum premium, so the setup stays a basing attempt under resistance rather than a breakout. The now-confirmed 2026-08-03 Q2 print (after close) is the binary that decides whether the guided reacceleration and the Smith+Nephew ramp are landing; a clean reclaim of ~$17 on a higher low is what would turn the name actionable.

Bullish and bearish views on SI-BONE, Inc.

The model's bull view on SI-BONE, Inc. (SIBN), in brief: Truist raised its target to $21 from $18 on 2026-07-16 (Richard Newitter, Buy maintained), reversing the post-Q1 cut and re-rating back toward the sell-side high. The bear view: Price is testing, not holding above, the 200-day/$17.05 resistance; the June–July action is a stall inside a $14.13–$17.05 range after a year spent below the 200-day with the 50-day beneath it. Both cases follow in full.

Bull Case

• Truist raised its target to $21 from $18 on 2026-07-16 (Richard Newitter, Buy maintained), reversing the post-Q1 cut and re-rating back toward the sell-side high.
• Q1 2026 (2026-05-11): revenue $52.6M, +11.2% YoY; US +10%, international +33.9%; gross margin ~79.8%; net loss narrowed to $4.3M; adjusted EBITDA positive.
• FY2026 guide raised to $230–233M (+14–16% YoY); consensus now models ~$236.3M revenue (+14.6%), with management guiding a second-half-weighted ramp.
• Smith+Nephew distribution agreement (signed 2026-02-23, rollout began March 2026) places iFuse TORQ / TORQ TNT into Level 1–2 trauma centers, layering a pelvic-fragility-fracture TAM onto the SI-joint base.
• iFuse TORQ TNT — the first 3D-printed transiliac-transsacral screw — holds FDA Breakthrough Device status and qualifies for CMS NTAP reimbursement up to $4,136 per case, a direct hospital adoption incentive.
• Active physician base above 1,650, +17% YoY, extending a multi-quarter double-digit run in the utilization base.
• Consensus is uniformly constructive: average target ~$19.67–21.20, high $27 (Needham 2026 Top Pick / Conviction List), low $18, all Buy/Strong Buy as of 2026-07-16; free-cash-flow profitability guided for 2026.

Bear Case

• Price is testing, not holding above, the 200-day/$17.05 resistance; the June–July action is a stall inside a $14.13–$17.05 range after a year spent below the 200-day with the 50-day beneath it.
• Q1 growth decelerated to +11.2%, and the 2026 EPS line is still negative (consensus −$0.44) — a mid-teens grower carrying GAAP losses, not the accelerating comp a momentum book pays up for.
• The FY guide bakes in a second-half reacceleration the tape has not confirmed; if the Smith+Nephew trauma ramp converts slower than modeled, the +14–16% guide is exposed at the 2026-08-03 print.
• Adjusted-EBITDA positivity and the promised free-cash-flow crossover are early and thin; a single soft quarter resets the profitability narrative.
• ~$750M market cap with thin float dynamics; institutional trimming (Sterling Capital, Two Sigma flagged over the past year) can override the fundamental story for quarters at a time.
• Earnings six trading days out makes any fresh position a binary bet rather than a momentum entry — the setup argues for standing aside until the print clears or the chart breaks out.

Setup & Price Structure

Spot ~$16.62 (late July 2026), inside an $11.48–$21.89 52-week range. The stock recovered off the ~$15.50 area into a consolidation that has now stalled directly under the $17.05 resistance overlapping the 200-day. The multi-week pattern is a higher-low base attempt, but the higher high — a close above ~$17 — has not printed, so the reclaim signal is unconfirmed. Support sits at $14.13; lose it and the structure breaks with the $11.48 low back in play. The June–July range is a tight $14.13–$17.05 coil, and the name is winding into its earnings date rather than trending into it. For a momentum entry the trigger is a daily/weekly close above ~$17 on a higher low with the 50-day turning up; nothing in the tape yet confirms that. The story (accelerating medtech theme, profitability inflection) and the price structure (below the 200-day, coiling) still disagree, though the gap has narrowed versus the spring.

Catalyst Calendar (next 30 days)

• 2026-08-03 (confirmed) — Q2 2026 results after market close, conference call 4:30 p.m. ET. First full read on the Smith+Nephew trauma ramp and the guided second-half reacceleration; the binary for the entire thesis. Avoid fresh entries into the print.
• Ongoing — Smith+Nephew trauma sales-force prioritization and iFuse TORQ TNT NTAP adoption are the swing factors management will be pressed on Aug 3.
• No FDA/PDUFA date pending within the window; the Aug 3 print is the only hard-dated catalyst in the next 30 days.

Elapsed catalysts

• 2026-07-16 (elapsed, context) — Truist raised target to $21 from $18, Buy maintained; watch for follow-on sell-side revisions clustering into the print. (passed 12d ago)

What Would Change Our Mind

A weekly close below $14 breaks the consolidation base and reopens the path toward the $11.48 52-week low — that ends the basing thesis outright. On the fundamental side, a 2026-08-03 print with revenue growth back below ~11% YoY, or a walk-back of the +14–16% FY guide, would confirm the trauma ramp and second-half reacceleration are not converting and would invalidate the profitability-inflection read. In the other direction, a decisive close above ~$17 on a higher low with the 50-day turning up — ideally confirmed by a Q2 beat and raised guide — flips the setup from basing-under-resistance to an actionable momentum entry and would justify stepping up size. A theme rotation to a saturated state with no fresh catalyst, or continued institutional distribution overwhelming the tape, keeps the name a stand-aside regardless of the fundamental story.

Correlation Notes

SIBN trades as a small/mid-cap spine-and-ortho medtech growth name, so it tracks peers like Globus Medical (GMED) and Nevro (NVRO) and small-cap health-care beta (IWM / XBI-adjacent risk appetite) more closely than the S&P 500. Because it remains GAAP-loss-making, it carries long-duration, rate-sensitive characteristics — a tightening-rate regime pressures the multiple independent of execution. Smith+Nephew (SNN) is the key idiosyncratic linkage: SNN's trauma sales-force prioritization directly gates SIBN's new growth leg, so SNN commentary and trauma-segment results are a live read-through. The Aug 3 print is idiosyncratic and can decouple the name from the group in either direction on a 10–30% single-day move.